ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 101 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $467,000 | -49.0% | 77,958 | -37.1% | 0.00% | -100.0% |
| Q4 2018 | $916,000 | -82.7% | 123,941 | -66.0% | 0.00% | -50.0% |
| Q3 2018 | $5,300,000 | +29.5% | 365,038 | +78.0% | 0.00% | -33.3% |
| Q2 2018 | $4,094,000 | +15.2% | 205,031 | +1.1% | 0.00% | +50.0% |
| Q1 2018 | $3,553,000 | -29.0% | 202,818 | 0.0% | 0.00% | -33.3% |
| Q4 2017 | $5,001,000 | -15.8% | 202,818 | -11.9% | 0.00% | -25.0% |
| Q3 2017 | $5,940,000 | +1.9% | 230,148 | +7.1% | 0.00% | 0.0% |
| Q2 2017 | $5,829,000 | +9.7% | 214,941 | +20.6% | 0.00% | 0.0% |
| Q1 2017 | $5,316,000 | +9.2% | 178,274 | -0.6% | 0.00% | 0.0% |
| Q4 2016 | $4,868,000 | +568.7% | 179,382 | +530.7% | 0.00% | – |
| Q3 2016 | $728,000 | +38.7% | 28,440 | 0.0% | 0.00% | – |
| Q2 2016 | $525,000 | +114.3% | 28,440 | +119.6% | 0.00% | – |
| Q1 2016 | $245,000 | -29.8% | 12,953 | 0.0% | 0.00% | – |
| Q4 2015 | $349,000 | – | 12,953 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |